The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer

Brown, Aaron; Chen, Jergin; Hitchcock, Ying J.; Szabó, Anikó; Shrieve, Dennis C.; Tward, Jonathan D.

doi:10.1210/jc.2007-1154

Cited by 342 publications

(337 citation statements)

References 38 publications

Supporting

Mentioning

312

Contrasting

Unclassified

Order By: Relevance

“…Considering the excess in solid cancers, and the type of tumours concerned, the data are highly divergent in the literature. Some authors [13] have reported a link between 131 I therapy and some solid cancers, which has not been confirmed by other studies [14].…”

mentioning

confidence: 80%

A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma

Zanotti‐Fregonara

Grassetto

Hindié

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

mentioning

confidence: 80%

A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma

Zanotti‐Fregonara

Grassetto

Hindié

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…In 2003, Rubino et al [37] reported that cumulative doses of RAI (Ͼ600 MCi, 22 GBq) are associated with a higher risk for leukemia. A greater risk for other secondary malignancies has also been reported [38,39]. Thus, the use of RAI should be individualized to balance the risks against the therapeutic benefit.…”

Section: Raimentioning

confidence: 99%

Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer

et al. 2010

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Describe the role and limitations of traditional treatments for metastatic differentiated thyroid cancer.2. Discuss the molecular basis of and clinical evidence for novel and emerging treatments for metastatic differentiated thyroid cancer.3. Identify suitable candidates for clinical trials among your patients with radioactive iodine refractory, metastatic differentiated thyroid cancer and enroll them.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTDifferentiated thyroid cancer accounts for >90% of cases of thyroid cancer, with most patients having an excellent prognosis. Distant metastases occur in 10%-15% of patients, decreasing the overall 10-year survival rate in this group to 40%. Radioactive iodine has been the mainstay of treatment for distant metastases, with good results when lesions retain the ability to take up iodine. For patients with metastatic disease resistant to radioactive iodine, treatment options are few and survival is poor. Chemotherapy and external beam radiotherapy have been used in these patients, but with disappointing results. In recent years, our understanding of the molecular pathways involved in thyroid cancer has increased and a number of molecular targets have been identified. These targets include the protooncogenes BRAF and RET, known to be common mutations in thyroid cancer; vascular endothelial growth factor receptor and platelet-derived growth factor receptor, associated with angiogenesis; and the sodiumiodide symporter, with the aim of restoring its The Oncologist CME Program is located online at http://cme.theoncologist.com/.To take the CME activity related to this article, you must be a registered user. EndocrinologyThe

show abstract

“…According to the American Thyroid Association (ATA) recommendations, after total thyroidectomy, 131-I administration is indicated in patients with moderate to high risk of recurrence based on age, tumour size, lymph node status, extrathyroidal extension, and the histological type of the thyroid tumour (Cooper et al 2009;Schlumberger and Sherman 2012). However, the significant radiation doses delivered to extrathyroidal tissues are associated with acute and long-term risks and side effects, including second primary malignancies (Rubino et al 2003;Brown et al 2008;Sawka et al 2009). …”

mentioning

confidence: 99%

Correlation between Micronuclei Frequency in Peripheral Blood Lymphocytes and Retention of 131-I in Thyroid Cancer Patients

Vrndic

Milošević-Djordjević

Mijatovic-Teodorovic

et al. 2013

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Differentiated thyroid cancers (DTCs) derive from thyroid follicular cells and include papillary and follicular cancers. In patients with DTCs, the initial treatment includes thyroidectomy and radioactive iodine (131-I) therapy. The objective of this study was to examine whether the intensity of DNA damage in peripheral blood lymphocytes (PBLs) of DTC patients depends on the amount of 131-I retained in the selected regions of interest (thyroid and abdominal region) as well as in the whole-body 72 hours after therapy. In addition, the possible influence of other factors that may affect micronuclei (MN) frequency, such as age, gender, smoking habits, and histological type of tumour was analyzed. The study population consisted of 22 DTC patients and 20 healthy donors. Data on the distribution of 131-I were obtained from the whole-body scans. MN frequency and cytokinesis-block proliferation index (CBPI) were measured using cytokinesis-block micronucleus assay. 131-I therapy significantly increased the MN frequency (19.50 ± 6.90 vs. 27.10 ± 19.50 MN) and significantly decreased the CBPI (1.52 ± 0.20 vs. 1.38 ± 0.17) in patients' lymphocytes. There was a clear correlation between the increased MN frequency and 131-I accumulation in the thyroid region in patients without metastases. The MN values did not differ in relation to the factors that could affect MN, such as age, gender, smoking habits, and histological type of tumour. In conclusion, the MN frequency in PBLs of DTC patients without metastases depends on the accumulation of 131-I in the thyroid region and does not depend on the other factors examined.

show abstract

The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer

Abstract: The overall risk of second primary malignancies is increased for thyroid cancer survivors and varies by radioisotope therapy, latency, and age at diagnosis.

Cited by 342 publications

References 38 publications

A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma

A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma

Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer

Correlation between Micronuclei Frequency in Peripheral Blood Lymphocytes and Retention of 131-I in Thyroid Cancer Patients

Contact Info

Product

Resources

About